Derivative settlement formalized: governance reforms, up to $3.9 million in fees

This is largely a procedural formalization, not a new settlement surprise. The parties reached the core agreement in December 2025 and signed the detailed settlement on January 19, 2026; this filing mainly presents the stipulation, notice materials, and proposed court orders. The settlement remains subject to final court approval. (Settlement Background; Preliminary Approval Order)

CorMedix receives governance changes rather than a cash recovery. The company must create a management-level disclosure committee, expand board oversight of compliance and reporting, add executive and director training, and strengthen its whistleblower program. Previously implemented manufacturing and legal/compliance changes are also credited to the settlement. The reforms must generally remain in place for at least 3.5 years, but can end if CorMedix is acquired or no longer public. (Exhibit A — Corporate Governance Reforms; Proposed Settlement Notice)

The main economic downside is the potential fee payment, with no offsetting damages recovery disclosed. Plaintiffs’ counsel may seek up to $3.9 million from CorMedix, although the amount is not agreed and the defendants may oppose it. The company also bears settlement-notice costs. In exchange, the derivative claims are released and dismissed with prejudice if approval becomes final. (Sections 4.1–4.2, 5.2, 7.2–7.3; Proposed Order and Final Judgment)

Net versus expectations: mixed, because the filing adds little that was not already known. There is no meaningful earnings or operating update to beat or miss, and the settlement’s essential terms were already established before this filing. The reforms address the disclosure and manufacturing-control allegations, but the company gets no direct cash benefit and faces a potentially material fee obligation. (Settlement Background; Sections 3.3–4.2)